Hutchmed Share News (HCM)

IN BRIEF: Hutchmed presents solid results from lung cancer study

Hutchmed China Ltd - Hong Kong-based biopharmaceutical company - Presents positive results from the Savannah phase two trial of Hutchmed and AstraZeneca PLC's savolitinib in combination with Astra's osimertinib in epidermal growth factor receptor-mutated non-small cell lung cancer patients.

AIM WINNERS & LOSERS: Hutchmed down amid China Covid woes; Parkmead up

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

Hutchmed phase I trial for IMG-007 doses first patient

(Alliance News) - Hutchmed China Ltd on Wednesday announced the first patient has been dosed for its phase I trial for IMG-007.

IN BRIEF: Hutchmed China wins cancer drug Tazverik approval in Hainan

Hutchmed China Ltd - Hong Kong-based biopharmaceutical company - Receives approval for Tazverik from the Health Commission & Medical Products Administration of the Hainan province in China. The approval is for use in the Hainan pilot zone under the Clinically Urgently Needed Imported Drugs scheme, for the treatment of certain patients with epithelioid sarcoma and follicular lymphoma.

LONDON MARKET MIDDAY: Stocks down as aggressive US Fed rate hike looms

(Alliance News) - Stock prices in London were lower at midday on Tuesday following the long bank holiday weekend in the UK, as markets globally prepare for a sharp US interest rate hike and similar moves by other central banks as they struggle to control inflation.

AIM WINNERS & LOSERS: Hutchmed sinks on US FDA drug rejection

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Tuesday.

IN BRIEF: US FDA says Hutchmed's pancreatic drug needs more testing

Hutchmed (China) Ltd - Hong Kong-based biopharmaceuticals - The US Food & Drug Administration has rejected Hutchmed's surufatinib for treatment of pancreatic neuroendocrine tumours. In a complete response letter, the FDA says the current data package, based on two positive phase three trials in China and one bridging study in the US, does not support an approval in the US "at this time". The FDA said a multi-regional clinical trial of surufatinib required for US approval. Surufatinib was approved in China for the treatment of pNETs and extra-pancreatic neuroendocrine tumours in June 2021 and December 2020, respectively. Chief Executive Officer & Chief Scientific Officer Weiguo Su comments: "Although this decision from the FDA is disappointing, we remain confident about the clinical value of surufatinib for NET patients and committed to making surufatinib available to patients globally. We look forward to working with the agency to evaluate its feedback."

LONDON MARKET OPEN: BP rises despite taking hit from Rosneft exit

(Alliance News) - Stock prices in London opened lower on Tuesday following the long bank holiday weekend, with BP shares rising as the oil major planned to return cash to shareholders amid calls by some UK politicians for a windfall profit tax on energy companies.

LONDON MARKET PRE-OPEN: BP swings to quarterly loss after Rosneft exit

(Alliance News) - Stock prices in London are seen opening lower on Tuesday, after the long bank holiday weekend in the UK, as concerns rise over aggressive monetary policy tightening by the US Federal Reserve.

AIM WINNERS & LOSERS: musicMagpie sells on new platform; Hutchmed down

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Monday.

UK shareholder meetings calendar - next 7 days

IN BRIEF: Hutchmed China named by SEC, might delist Nasdaq shares

Hutchmed China Ltd - Hong Kong-based biopharmaceutical company - US Securities & Exchange Commission identifies Hutchmed China under the new Holding Foreign Companies Accountable Act, which identifies public companies who have used auditors from overseas or auditors who are unable to be investigated completely. The new regulation has no impact on business operations, Hutchmed says.

Hutchmed China confident after being added to SEC list

(Sharecast News) - Hutchmed China updated the market on its status under the United States 'Holding Foreign Companies Accountable Act' on Thursday.

AIM WINNERS & LOSERS: Omega Diagnostics Visitect not available in UK

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Friday.

IN BRIEF: Hutchmed China shares fall as US listing under threat

Hutchmed (China) Ltd - Hong Kong-based biopharmaceutical company - Says its depositary shares may be delisted from New York's Nasdaq exchange in early 2024 unless the Holding Foreign Companies Accountable Act is amended to exclude Hutchmed. The act is part of regulatory focus in the US on access to audit and other information. It requires the US Securities & Exchange Commission to prohibit the securities of any company from being traded on any of the US securities exchanges if the auditor of the company's financial statements is not subject to inspection by the US Public Co Accounting Oversight Board for three consecutive years. Another way for Hutchmed to be excluded from the act is if the PCAOB is able to conduct a full inspection of the company's auditor during the required timeframe.